Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
06
02
2023
accepted:
12
06
2023
revised:
05
05
2023
pmc-release:
30
06
2024
medline:
8
11
2023
pubmed:
1
7
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
The past decade has witnessed a revolution in cancer treatment by the shift from conventional drugs (chemotherapies) towards targeted molecular therapies and immune-based therapies, in particular the immune-checkpoint inhibitors (ICIs). These immunotherapies selectively release the host immune system against the tumour and have shown unprecedented durable remission for patients with cancers that were thought incurable such as advanced non-small cell lung cancer (aNSCLC). The prediction of therapy response is based since the first anti-PD-1/PD-L1 molecules FDA and EMA approvals on the level of PD-L1 tumour cells expression evaluated by immunohistochemistry, and recently more or less on tumour mutation burden in the USA. However, not all aNSCLC patients benefit from immunotherapy equally, since only around 30% of them received ICIs and among them 30% have an initial response to these treatments. Conversely, a few aNSCLC patients could have an efficacy ICIs response despite low PD-L1 tumour cells expression. In this context, there is an urgent need to look for additional robust predictive markers for ICIs efficacy in thoracic oncology. Understanding of the mechanisms that enable cancer cells to adapt to and eventually overcome therapy and identifying such mechanisms can help circumvent resistance and improve treatment. However, more than a unique universal marker, the evaluation of several molecules in the tumour at the same time, particularly by using multiplex immunostaining is a promising open room to optimise the selection of patients who benefit from ICIs. Therefore, urgent further efforts are needed to optimise to individualise immunotherapy based on both patient-specific and tumour-specific characteristics. This review aims to rethink the role of multiplex immunostaining in immuno-thoracic oncology, with the current advantages and limitations in the near-daily practice use.
Identifiants
pubmed: 37391504
doi: 10.1038/s41416-023-02318-7
pii: 10.1038/s41416-023-02318-7
pmc: PMC10628288
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1417-1431Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362
pubmed: 33580222
Lung Cancer. 2018 Oct;124:90-94
pubmed: 30268486
Immunity. 2020 Jan 14;52(1):55-81
pubmed: 31940273
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Pathol Clin Res. 2022 Mar;8(2):101-115
pubmed: 34796679
Nat Med. 2018 Oct;24(10):1559-1567
pubmed: 30224757
J Thorac Oncol. 2022 Dec;17(12):1335-1354
pubmed: 36184066
Front Mol Biosci. 2021 Aug 31;8:660202
pubmed: 34532339
Lung Cancer. 2022 Apr;166:1-8
pubmed: 35134710
Nat Med. 2019 Oct;25(10):1519-1525
pubmed: 31591589
J Histochem Cytochem. 2009 Oct;57(10):899-905
pubmed: 19365090
Cancer Commun (Lond). 2020 Apr;40(4):135-153
pubmed: 32301585
Nat Protoc. 2021 Aug;16(8):3802-3835
pubmed: 34215862
J Thorac Dis. 2019 Jan;11(Suppl 1):S71-S80
pubmed: 30775030
Ann Oncol. 2022 Feb;33(2):169-180
pubmed: 34800678
Clin Cancer Res. 2022 Nov 14;28(22):4835-4837
pubmed: 36103258
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Clin Transl Med. 2022 Aug;12(8):e1018
pubmed: 35994416
Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246
pubmed: 30339766
Elife. 2018 Jul 11;7:
pubmed: 29993362
Clin Cancer Res. 2021 Jul 1;27(13):3620-3629
pubmed: 33883177
Clin Cancer Res. 2019 Aug 1;25(15):4663-4673
pubmed: 31053602
Methods Enzymol. 2020;635:1-20
pubmed: 32122539
Cancer Cell. 2022 Aug 8;40(8):865-878.e6
pubmed: 35944502
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Science. 2021 Jun 11;372(6547):
pubmed: 34112666
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Bioconjug Chem. 2016 Mar 16;27(3):660-6
pubmed: 26731201
Cancer Commun (Lond). 2020 Apr;40(4):154-166
pubmed: 32277744
Ann Oncol. 2021 May;32(5):661-672
pubmed: 33736924
Virchows Arch. 2016 May;468(5):511-25
pubmed: 26915032
Mod Pathol. 2022 Jan;35(Suppl 1):66-74
pubmed: 34608245
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34266881
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
Cancers (Basel). 2019 Feb 20;11(2):
pubmed: 30791580
Am J Pathol. 2021 Oct;191(10):1684-1692
pubmed: 33245914
Lab Invest. 2017 Jul;97(7):873-885
pubmed: 28504684
Clin Cancer Res. 2023 Jan 17;29(2):316-323
pubmed: 36083132
Cancers (Basel). 2020 Jan 21;12(2):
pubmed: 31972974
Clin Cancer Res. 2021 Sep 1;27(17):4685-4689
pubmed: 34083238
Methods Enzymol. 2020;635:33-50
pubmed: 32122552
Genes (Basel). 2021 Apr 07;12(4):
pubmed: 33917241
J Am Med Inform Assoc. 2015 Jan;22(1):86-99
pubmed: 25125687
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35217575
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Front Oncol. 2022 Jul 29;12:918900
pubmed: 35992810
Front Oncol. 2022 Jun 27;12:889886
pubmed: 35832550
Eur J Cancer. 2022 Feb;162:1-10
pubmed: 34936940
Biosensors (Basel). 2022 Nov 17;12(11):
pubmed: 36421151
Ann Oncol. 2019 Sep 1;30(9):1448-1459
pubmed: 31228184
Nat Commun. 2018 Aug 10;9(1):3196
pubmed: 30097571
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Sci Immunol. 2016 Jul 14;1(1):aaf6925
pubmed: 28783673
Nat Rev Clin Oncol. 2019 Nov;16(11):703-715
pubmed: 31399699
Lab Invest. 2020 Aug;100(8):1124-1136
pubmed: 32341516
Lab Invest. 2017 Jan;97(1):104-113
pubmed: 27869794
Cancer Cell. 2022 Mar 14;40(3):289-300.e4
pubmed: 35216676
Cancers (Basel). 2019 Feb 27;11(3):
pubmed: 30818873
Mod Pathol. 2022 Jan;35(1):23-32
pubmed: 34611303
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Methods Protoc. 2019 May 28;2(2):
pubmed: 31164623
Mod Pathol. 2022 Feb;35(2):152-164
pubmed: 34599281
Biomark Res. 2020 Aug 26;8:34
pubmed: 32864131
Front Mol Biosci. 2021 Jun 02;8:674747
pubmed: 34150850
Methods Mol Biol. 2020;2055:497-519
pubmed: 31502167
Nat Cancer. 2022 Jun;3(6):652-656
pubmed: 35764740
Int J Cancer. 2020 Sep 15;147(6):1509-1518
pubmed: 31997345
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Clin Cancer Res. 2021 Sep 15;27(18):5072-5083
pubmed: 34253580
J Pathol. 2022 Jul;257(4):391-402
pubmed: 35481680
Front Mol Biosci. 2023 Feb 09;10:1051491
pubmed: 36845550
Nat Cancer. 2022 Oct;3(10):1151-1164
pubmed: 36038778
Clin Transl Immunology. 2020 Oct 07;9(10):e1183
pubmed: 33072322
Front Mol Biosci. 2022 Feb 25;9:831383
pubmed: 35281257
J Thorac Oncol. 2020 Sep;15(9):1535-1540
pubmed: 32450274
J Histochem Cytochem. 2022 Aug;70(8):571-581
pubmed: 35848523
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Cancers (Basel). 2020 Sep 21;12(9):
pubmed: 32967325
Diagnostics (Basel). 2021 Nov 22;11(11):
pubmed: 34829514
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35131861
Sci Adv. 2022 Jun 3;8(22):eabn3966
pubmed: 35648850
JAMA Oncol. 2019 Aug 01;5(8):1195-1204
pubmed: 31318407
Lab Invest. 2020 Aug;100(8):1111-1123
pubmed: 32203152
J Thorac Oncol. 2021 Aug;16(8):1247-1249
pubmed: 34304853
Nat Biotechnol. 2006 Oct;24(10):1270-8
pubmed: 17013374
Arch Pathol Lab Med. 2017 Jul;141(7):944-959
pubmed: 28440660
Biotechnol J. 2021 Sep;16(9):e2100041
pubmed: 34125481
Methods Mol Biol. 2020;2055:467-495
pubmed: 31502166
Nat Methods. 2021 Sep;18(9):997-1012
pubmed: 34341583
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Nat Rev Immunol. 2022 Apr;22(4):209-223
pubmed: 34253904
Cancers (Basel). 2018 Sep 13;10(9):
pubmed: 30216999
Transl Lung Cancer Res. 2020 Dec;9(6):2311-2314
pubmed: 33489794
Eur J Immunol. 2022 Jan;52(1):96-108
pubmed: 34505280
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
J Immunother Cancer. 2020 May;8(1):
pubmed: 32414858
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
JAMA Oncol. 2022 Aug 1;8(8):1160-1168
pubmed: 35708671
J Clin Oncol. 2022 Jun 10;40(17):1916-1928
pubmed: 35271299
Cancer Treat Res. 2022;183:185-199
pubmed: 35551660